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University of Manchester, Universities of Liverpool and Central Lancashire, 
University of Manchester, University of Manchester, University of 
Manchester & University of Manchester, UKabstract General practitioner (GP) prescribing has been identifi ed as an 
arena that has broad social and political implications, which stretch beyond 
individual outcomes for patients. This article revisits aspects of the contro-
versy about prescribing benzodiazepines (or ‘minor tranquillizers’) through 
an exploration of contemporary views of GPs. In the 1980s the prescribing 
of these drugs was considered to be both a clinical and social problem, which 
brought medical decision making under public scrutiny. The legacy of this 
controversy for recent GPs remains a relatively under-explored topic. This 
article describes a qualitative study of GPs practising in the north-west of 
England about their views of prescribing benzodiazepines. The accounts of 
the respondents highlight a number of points about: blame allocation, past 
and present; clinical challenges about risk management; and deserving and 
undeserving patients. These GP views are then discussed in the wider context 
of psychotropic drug use. It is concluded that, while there has been a recent 
consensus that the benzodiazepines have been problematic, when they are 
placed in a longer historical context, a different picture is apparent because 
other psychotropic drugs have raised similar problems.
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In the past, sociologically informed studies have highlighted the impact of 
the consultation on social and clinical outcomes, for patients in primary care 
(May et al., 2004). In particular, the prescribing of medication in primary 
care has been identifi ed as an area where the legitimacy and moral authority 
of the doctor is enacted (Britten et al., 2004). It is also a health care arena 
where the power and infl uence of patients can be enhanced (through shared 
decision making) or thwarted through the embedded power imbalance 
between GP prescription preferences and those of recipients (Stevenson
et al., 2002; Britten et al., 2004).
This article has three aims. First, a brief history will be given about the 
social and clinical controversy which has attended a particular area of 
medical practice – the prescription of benzodiazepines. This controversy 
peaked in the mid-1980s but the drugs were prescribed at high rates beyond 
that period (Medawar, 1992). Second, a qualitative study of recent GP views 
about the use of this group of drugs is reported. This explores the way in 
which contemporary practitioners view an emotive and controversial area 
of prescribing, one in which the actions and professional norms of GPs have 
been implicated in creating and maintaining a form of clinical iatrogenisis. 
The intention here is to explore the views of current practitioners, many of 
whom were not in their current post or training at the start of the controversy, 
but who are now dealing with its consequences in their clinical work. Third, 
these current views and their historical roots will be discussed in relation 
to the general context of psychotropic drug responses to the psychosocial 
features of mental health problems.
The medical rationale for benzodiazepine use and the emergent 
controversy
The fi rst benzodiazepine, chlordiazepoxide (Librium) was introduced into 
clinical practice in 1960. This and related products (such as Valium, Xanax 
and Ativan) came to be prescribed in large quantities. They have been used 
for a variety of medical purposes, including the brief tranquillization of 
surgical patients, the treatment of epilepsy, as an aid to withdrawal from 
alcohol abuse and to calm psychotic agitation. However, their main use has 
been for the treatment of anxiety and insomnia. In the clinical literature, 
the drugs are classifi ed as ‘anti-anxiety agents’, ‘anxiolytics’ or ‘minor 
tranquillizers’.
The notion of ‘minor tranquillizers’ (rather than the drugs merely be-
ing about the removal of anxiety symptoms) is warranted for two reasons. 
The fi rst is pharmacological – chlordiazepoxide was synthesized from chlor-
promazine (the fi rst ‘major’ tranquillizer’) in 1955. The second reason for 
calling them ‘tranquillizers’ is the impact of benzodiazepines on the central 
nervous system and on behaviour. These drugs, like alcohol, can lead to 
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euphoria and disinhibition as well as sedation and sleepiness. These effects 
raise the probability of risky behaviour – they can impair motor tasks, create 
dangers when driving or using machinery and release emotions that might 
be expressed antisocially. Thus, the generic tranquillizing effect of the drugs 
does more than remove anxiety; it also dampens sensibility, impairs com-
petence and can loosen normal social and moral inhibitions.
Like other tranquillizing drugs (for example the barbiturates and alco-
hol) the benzodiazepines reinforce the action of a naturally occurring neu-
rotransmitter (gamma-aminobutyric acid or GABA). GABA has a general 
calming effect on neural activity. As a consequence, once the nervous sys-
tem habituates to the artifi cial booster effect of GABA levels, it becomes 
excited if the external agent is withdrawn. A consequence of withdrawal is 
heightened anxiety; a ‘rebound’ or iatrogenic effect of benzodiazepine use.
Because of this GABA effect, the benzodiazepines were soon noted to 
have similar disadvantages to previously preferred sedatives and hypnotics, 
such as paraldehyde and the barbiturates. All of these anti-anxiety agents 
were associated with tolerance and thus the need for increasing dose levels. 
The benzodiazepines, like their predecessors, have been characterized by 
psychological and physiological dependence, so their prescription has led 
to predictable iatrogenic addiction. The latter has meant that clinical time 
and effort and health care resources have had to be devoted to treating 
iatrogenic rather than primary symptoms of mental health problems.
Thus the controversy about benzodiazepines in one sense was not new; 
previous anti-anxiety agents had been linked to similar problems. Healy 
(1997) describes a cycle of legitimacy associated with drugs that are highly 
prescribed for symptoms of common distress (be it anxiety, depression or 
their frequent co-occurrence). For example, prior to the benzodiazepines, 
the bromides of the 1920s gave way by the 1940s to the barbiturates. Simi-
larly, the benzodiazepines have now given way to the antidepressants.
This is not merely about one fashionable named drug (say Valium) being 
displaced by another (say Prozac), although this is partially the case. It also 
includes unique selling points of newer drugs, which claim a legitimate 
advantage over past agents. For example, the benzodiazepines are not 
very toxic even in high doses, whereas twice the prescribed dose of the 
barbiturates could be fatal (though it should be noted that several weeks 
supply of the former, if ingested with alcohol, can still kill).
Notwithstanding this unique selling point of the benzodiazepines, rapid 
tolerance means that they become clinically ineffective after a very short 
period (around 10 days), with 58  – 77 per cent of recipients reporting sedation 
effects of the drugs (drowsiness, lethargy and memory disturbances) (Lader 
et al., 1992). Thirty per cent of those taking these drugs for more than a 
few weeks develop withdrawal symptoms, including panic attacks, insomnia, 
tremor, palpitations, sweating and muscle tension (Tyrer, 1987). In a small 
percentage (under 5 per cent) more severe problems, including epileptic 
seizures and paranoid reactions, might occur (Baldessarini, 1999).
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While these problems were recognized as early as the mid-1960s in 
the USA, and a law suit was instigated by the US government against the 
pharmaceutical company Roche in 1967, it was not until the 1980s that 
the problem was recognized politically in the UK. This culminated in the 
banning and suspension of some drugs. Both a limited and black list of drugs 
licensed for prescription was then implemented and advice on prescribing 
was drawn up and issued (Committee on the Safety of Medicines, 1988).
During the 1980s, prescription levels began to fall, but mainly for their use 
as anxiolytics. Rates of their prescription as sleeping tablets (the same drug 
is then called a ‘hypnotic’) actually increased slightly. Also, this period of 
heightened professional concern did not lead to the medical abandonment 
of the drugs. In 1980 there were 23 million prescriptions of benzodiazepines 
issued in England. Ten years later there were still 16 million prescriptions of 
the drugs issued (Tyrer et al., 1997, using government-disclosed data).
The extent of the problem was illustrated by a MORI poll conducted 
in 1985, which suggested that 10 million UK citizens had been prescribed 
benzodiazepines at some time in their lives and that 3 million people were, at 
that time, ‘chronic’ users. However, Healy (1997) makes the important point 
that common distress has always led to psychotropic agents (including ones 
prior to and since the benzodiazepines) being highly prescribed. Because 
neurotic distress is highly prevalent, medical practitioners consulted will 
tend to prescribe highly in response (compared to less common ailments). 
This does not negate the reality of the iatrogenic scale of benzodiazepine 
addiction. However, it does place it in the context of other commonly 
prescribed agents over time and it is a proxy measure of common neurotic 
misery.
During the 1980s, the scale of iatrogenic addiction prompted a popular 
protest movement co-ordinated by the British mental health charity MIND 
and the popular BBC TV programme That’s Life, which led to further 
litigation against the drug companies (Lacey, 1991). Other social responses 
ensued. For example, self-help groups (such as ‘Tranx’) which were run 
by ‘ex and partially withdrawn addicts’, emerged specifi cally to deal with 
iatrogenic addiction (http://www.benzo.org.uk/). In this respect, the UK 
response mirrored the problem identifi cation and reaction that had occurred 
previously in the USA (Cohen, 1983).
Media attention regarding the iatrogenic effect of benzodiazepines 
occurred in the late 1970s and early 1980s in the USA (Cohen, 1983). In the 
UK, Bury and Gabe (1990) pointed up the role of the media in legitimizing 
the social problem status of the benzodiazepines. They identifi ed four social 
process elements: the claims-making activities of medical experts; legal 
challenges; the role of the media; and the response of the State. Together 
these four processes made a contribution to this class of drugs becoming a 
public and governmental, rather than merely a clinical, matter.
While these wider social infl uences, institutions and processes had a 
profound impact on the use and acceptability of benzodiazepines, the 
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problem could be readily reduced in the public eye to one of incompetent 
GPs ‘hooking’ innocent housewives on addictive and dangerous drugs. At 
that time (the early 1980s) evidence emerged that women consumed twice 
the amount of GP-prescribed psychotropic medication as men (Cooperstock, 
1978; Olson and Pincus, 1994). A complex set of social processes could 
then be reduced to poor GP judgement and gender vulnerability. This had 
the effect of both focusing blame on one profession and framing women 
as inherently psychologically weak. At the same time, it was evident that 
women would selectively use medication as part of a daily management 
regime to cope in diffi cult circumstances (Gabe and Thorogood, 1986).
In the immediate aftermath of the public outcry about benzodiazepines, 
various guidelines were issued to doctors concerning the treatment of 
anxiety and the use of this class of drugs. In line with this, research about 
prescribing since then suggests compliance with a much more restrictive 
repertoire. Currently, the level of benzodiazepine prescribing is a measure 
of quality used by Primary Care Trusts in England.
There is also now evidence of a shift towards patient self-regulation and 
active self-management by users, rather than dominance and control by pre-
scribers (North et al., 1995). There remains a continuing professional and 
patient interest in the risk of these drugs. A recent qualitative study under-
taken in Queensland, Australia suggested that the role of dependence in 
continued benzodiazepine use is well recognized, along with the importance 
of lifestyle change in its cessation. However, benzodiazepine users still ask 
GPs to provide advice about non-pharmacological management of their 
problems and the potential adverse consequences of long-term use prior to 
being prescribed benzodiazepines (Parr et al., 2006).
A qualitative study of current GP views about benzodiazepines
While there is emerging evidence that patients with mental health problems 
express a preference for seeing GPs rather than specialists (Lester et al., 
2005), the impact of the benzodiazepine controversy may have shaped 
recent prescribing patterns among GPs and affected their general approach 
to primary mental health care. Certainly the dominance of secondary care 
views about primary mental health care and the expert role assumed by 
psychiatrists are likely to have reinforced uncertainties that GPs may have 
had in relation to operating assertively and independently (Rogers and 
Pilgrim, 2001). In this light, a study was conducted to explore the dilemmas 
the legacy of the benzodiazepine controversy has created for recent practi-
tioners. Below, personal accounts from practising GPs are summarized and 
analysed thematically to shed light on this legacy.
Semi-structured interviews were carried out on a sample of 22 GPs 
drawn from a variety of localities across a major north-western English city. 
They included both male (n = 15) and female GPs (n = 7), newly qualifi ed 
practitioners and those who had been practising for a considerable period 
186
health: 11(2)
of time. GPs from a variety of practices (from single-handed to large group 
practices) were included in the study. The respondents were drawn from a 
total sampling frame of 70 GPs who participated in or host undergraduate 
medical education in their practices. Both university and NHS Ethics 
Committee approval was obtained.
As this was an exploratory qualitative study, a purposive attempt was 
made to capture the voices of GPs of different ages working in different 
clinical settings and those who had been involved in prescribing benzodi-
azepines during the 1980s and in the contemporary period. However, there 
was a bias towards younger GPs, who had been practising for a relatively 
short period of time. Despite targeting a group of GPs, who were older or 
who had been practising for a time, only a handful of the GPs (n = 5) who 
had been practising in the 1980s agreed to be interviewed. In one sense this 
can be seen as a limitation of the study. However, this reluctance to be inter-
viewed and failure on the part of interviewers to engage this group of GPs 
could have arisen for a range of reasons (e.g. being busier than their more 
junior colleagues or more jaded and less willing to participate in research). 
However, it may also refl ect the blame, shame and lingering responsibility 
felt by longer-practising GPs. That cohort of practitioners had been caught 
up in the adverse publicity of the time.
Interviews, which were conducted in these various settings explored 
practitioners’ views of the management of anxiety in general practice; 
the role of benzodiazepines in this management; and the types of patients 
that might still warrant repeat prescriptions of these drugs. The interview 
schedule was devised after reading relevant literature about benzodiazepine 
prescribing and use and it was modifi ed in the light of emerging data.
The interviews were taped and transcribed and themes agreed between 
the fi ve researchers. Interviews were carried out at two time periods, which 
were determined by the availability of the researchers (May  –  June 2001 and 
May – July 2002). The fi gure of 22 subjects occurred, when content saturation 
occurred in the transcripts in relation to broad headings structuring the 
interviews.
An initial categorization of themes was generated during the period of 
interviewing and moderated through discussion between the researchers. 
The initial categories were reduced to major and sub-themes, through read-
ing and re-reading of the transcripts. The four main themes emerging across 
all of the transcripts are now summarized.
The appropriateness of prescribing benzodiazepines
For the majority of respondents, a sense of responsibility for avoiding the 
risks associated with past benzodiazepine use framed contemporary ‘para-
meters’ of appropriate prescribing. Caution, vigilance and regulation were 
emphasized, along with a sense of ownership of practitioner responsibility 
for rectifying past errors of judgement and failings. A few of the respondents 
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felt that the social and clinical problem of the drugs had been overstated (see 
later) but the bulk of them were very concerned to minimize their use and 
the risks attached.
Judgements about the blame or responsibility for the past mistakes of 
overuse and inappropriate use centred on norms:
To blame GPs is probably too strong but to say that they were a contributory 
factor is to state the obvious really, when they were the people prescribing them. 
But I think that they were probably prescribed in good faith – that they were the 
correct treatments at that time and you know only subsequently did problems 
come to light. So I think to apportion blame is probably not right but clearly GPs 
were part of the picture. (GP-8)
Although the ‘blame’ for past problems was not always accepted as being 
caused by GP action alone, respondents acknowledged transmitted respon-
sibility for past events. Most respondents had not been trained GPs during 
the 1980s, but had been sensitized to the benzodiazepine problem as medical 
students (rather than having learnt about it subsequently through reports 
in medical journals or post-qualifi cation training). The GPs reported the 
belief that initially it was psychiatrists who often initiated prescribing. While 
recently psychiatrists predominantly have focused on the management of 
psychosis, at the time of the emergence of the benzodiazepine problem they 
would regularly see outpatients with problems of anxiety and depression 
who were not, as now, managed in primary care.
Past problems were attributed to the nature of drugs, the comparative 
lack of an evidence base and the way in which drug companies operate.
I think part of the responsibility lies in the drug companies that produce them in 
the fi rst place and I don’t think, well in those days there weren’t that many trials 
and things into these sorts of medications and their side-effects. I don’t think, well 
I don’t think doctors knew how addictive they were at the time, ’cos otherwise I 
think they’d have defi nitely thought twice about prescribing ... (GP-10)
Medical confi dence to prescribe a drug with apparently no reported adverse 
effects meant that its widespread utilization went unabated when the drugs 
were kick-started in the market after 1960. The respondents considered that 
this early optimistic therapeutic ethos has now been being replaced with 
one of cautiousness as indicated by this respondent:
I think there’s been an interesting change in the last 20 years in that I think you 
could say that there was a certain naivety and that if you, if anybody, now that 
I’m 50 said to me, ‘Here’s a great drug for anxiety which people can take long 
term and doesn’t have any addictive effects’ I simply wouldn’t believe them. But 
the fact was that when I qualifi ed that was what we believed, as of course it was 
believed for barbiturates 20 years before that. So I think, you know, you can only 
keep up with what appears to be acceptable medical practice at the time, bearing 
in mind things change. So I don’t feel particularly bad about that because it wasn’t, 
as it were, taught to me as a no-no thing to do at medical school. (GP-7)
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This older GP was in a position to have lived through the shift in conscious-
ness about the benzodiazepines and could offer some empathy with that 
hindsight. By contrast, most of the other respondents were younger and had 
been sensitized at medical school to the ‘no-no’ status of the drugs.
The origin of the problems of over-prescribing and turning a blind eye 
to the addictive features of the drugs were not always accepted as having 
been the sole responsibility of GPs; psychiatrists were seen as the source 
of the prescription habit. The respondents were keen to emphasize that a 
focus on GPs has been unreasonable, given that the psychiatric profession 
was deemed to be responsible for initiating and legitimizing the use of the 
drugs.
In the more recent climate of GPs defi ning their clinical autonomy about 
mental health problems, the respondents did feel a sense of continuity 
about professional responsibility. The younger respondents, for temporal 
reasons, logically had no personal responsibility for past mistakes but they 
still wanted to signal their professional duty as inheritors of a problem, as 
well as signalling their sympathy for predecessors in primary care:
I think that my perception was that actually what the GPs were doing was 
following what the psychiatrists did … because in the 70s patients with anxiety 
disorders would be seen by a psychiatrist. They would recommend a benzo and 
then the GP would continue that prescription. So the GPs got blamed but often 
they didn’t initiate … (GP-14)
Thus the current discourse of GPs (contra the one depicted in the 1980s) 
seems to be one of locating the medical diffi culty in psychiatry, in the past, 
rather than with their primary care predecessors alone.
Managing the past, managing the present
While the causes of past problems included an analysis that implicated 
psychiatric colleagues, there was a clear acceptance that GPs were now the 
sole guardians of the moral responsibility for appropriate prescribing and 
for rectifying the consequences of historical prescribing. A legitimate and 
expected part of the GP’s role now is to wean people off drugs to which they 
had inadvertently become addicted, for whatever reason, in the past. This is 
now acknowledged as a substantial clinical challenge: 
The addiction is so well known about that I think we all would just try and avoid 
using them for that reason … you don’t need to be on them for long for problems 
(to arise) … they’ve got a bad reputation. (GP-3)
GPs viewed initiating a programme of withdrawal as a part of their role 
in reversing the previous consequences of prescribing and they identifi ed 
specifi c ways and means to achieve this end. A number of respondents 
described how they would go about this with patients: ‘I’d just sort of sit down 
and negotiate and say, “you know, there are problems with this medication 
and let’s gradually wean you off it”. That straight forward …’ (GP-2). Other 
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GPs made a point of how they would do this without producing withdrawal 
symptoms: ‘We would gradually try and reduce, and certainly if they’re on 
a mixed bag of benzos then we would say, convert them over to diazepam 
and gradually reduce’ (GP-4). Another GP pointed out the importance of 
moving a long-term user of multiple benzodiazepines onto just one drug 
and then weaning the person off it subsequently.
In initiating new prescriptions, clear rules operated. The clinical rationale 
for initiating the drugs was narrowly defi ned and circumscribed. Issuing a 
limited number of tablets over a short period of time was emphasized, as 
was the need to be stringent about their use at all: ‘I don’t use them in anxi-
ety because they’re of such a limited benefi t … I think the indication for 
benzodiazepines in general practice is fairly limited really’ (GP-16). Here 
another respondent emphasizes cautious discretion in specifi c cases:
I’m most likely to initiate it in, for short-term problems and would generally 
prescribe in very small amounts then of perhaps half a dozen tablets. So I have 
got patients who, as it were, regularly but infrequently have that sort of amount 
of medication. (GP-7)
Retaining strict control of prescribing was seen as something that was 
to be policed robustly. Moreover, patient-led demand was suspended in 
relation to this type of drug, as was the more liberal ‘empirical’ or ‘try it and 
see’ approach, adopted by GPs in relation to non-controversial drugs. For 
the respondents, it was important to convey the exceptional and deserving 
circumstances of prescribing. Such cautiousness served to point up the 
image of the benzodiazepines being handed out like ‘Smarties’, which had 
been at the heart of the charge of GP irresponsibility in the past:
Maybe they’ve got a fear of fl ying and they haven’t got time to go on a phobia 
course or whatever and they’re going on holiday in a week’s time, then sure I give 
them a prescription. (GP-2)
I think they’re very useful in certain situations of acute anxiety, particularly I 
suppose in terminal situations when people are dying … because they’re unable 
to control the anxiety. (GP-11)
This last comment leads to the next signifi cant theme about justifying the 
circumstances and the type of patients that warrant the drugs.
Deserving and undeserving patients
Narratives about appropriate prescribing were littered with descriptions of 
the type of patient who could legitimately consult and be given benzodiaz-
epines. These descriptions were discussed in relation to two imperatives in 
tension with one another: the moral obligation to ensure a programme of 
humane withdrawal; and the strict need to restrict access to a wider popula-
tion. This tension is managed within the daily working constraints of GPs. 
Rather than the ‘housewife hooked on tranquillizers’, a converse picture 
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of the ‘needy’ patient emerged. Moreover, undeserving groups were those 
who do not elicit sympathy in the public eye and implicated GPs in a felt 
moral and legal responsibility. GPs labelled drug addicts and alcoholics as 
‘undeserving’ patients. Substance abuse was a key clinical feature to attend 
to in decision making:
So if somebody was already alcoholic they they’re not gonna get a hypnotic, 
whatever their circumstances really … (GP-19)
Certainly anybody with a history of addiction of alcohol abuse, drug abuse of any 
kind those would be the main ones [to be excluded]. (GP-17)
It’s the black market and the drug scene in [the city]. We have people who come 
in and you don’t know if they’re addicted or they’re going to sell them. (GP-12)
We have a practice policy that we don’t prescribe benzodiazepines to drug 
addicts. (GP-5)
Together these respondents were highlighting several disincentives about 
prescribing to substance abusers. First, it is wasteful of resources. Second, 
it may support an illicit street market in psychotropic drugs. Third, it may 
unhelpfully feed an addictive habit. In the latter regard, the issue is not about 
prescribing psychotropic drugs in principle but prescribing the ‘wrong’ drug 
(for example, methadone is prescribed to heroin users). We return to a 
discussion of this point about the ‘wrong’ drugs later. The medical framing 
of patients as morally worthy or unworthy is not new but an enduring and 
salient theme within medical sociology (Stimson and Webb, 1975; Jeffries, 
1979). But in addition to this general tendency in some medical encounters, 
there is a particular moral onus for the modern GP to display scrupulous 
prescribing rectitude, given the reputation of past colleagues when they 
issued benzodiazepines. They are repairing this past reputation in a context 
of drugs with a street value. These considerations are thus more complex 
than simply the wider medical tendency to label patients as worthy or 
unworthy.
Turning to ‘deserving’ patients these, by exclusion, were those who otherwise 
were not abusing substances and who, for clinical reasons, invited sympathy. 
The dying patient was noted earlier but more commonly it was the chronic 
user who had suffered iatrogenic addiction from the past: ‘It’s the stereotypical 
situation of the little old lady on her sleeper … the sort of the sleeper at night’ 
(GP-3). The following deserving case shows that in some contexts the normal 
aversion to offering the drugs to patients with a drink problem noted earlier 
can be overridden by some GPs sympathetic to the personal plight of some 
patients:
The commonest is people with those long-term life problems, bad unhappy 
marriages, maybe have a partner who’s a drinker, has a drinking problem 
themselves. It’s hard to generalize but, yeah, you know, domestic violence, 
dysfunctional relationships, whatever. People end up on them and stay on them. 
(GP-2)
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Notwithstanding this personal exception about drink problems, dichoto-
mization into deserving and undeserving patients was common in the accounts. 
Restricted use meant that these drugs were reserved for special circumstances 
and particular deserving patients, reversing the old image of the drugs being 
handed out indiscriminately for people with psychosocial problems. However, 
for some GPs the prescription acted as a buffer against dealing with the 
complexities of the latter. This respondent recognized this temptation and 
was critical: ‘Sometimes I think short-term use just puts off confronting what 
the real issues are either for me or even for the patient’ (GP-2). Thus, patients 
with overwhelming life circumstances were viewed as legitimate recipients 
of the benefi ts of tranquillizers in the absence of an alternative. Despite 
identifying the restricted circumstances under which prescriptions should 
have been offered, extreme life situations tempt GPs to issue the drugs as a 
means of rescuing distressed patients. The psychosocial needs of patients and 
the demands these placed on GPs meant that they, like their patients, felt like 
they had limited options.
They’re unemployed … they’re people who have the sort of common ghastly life 
circumstances that just keep on coming, you know, it not just previous life events 
and one day they’ll get over it, they just seem to keep on coming. Because of their 
situation in life they are still linked to very dysfunctional families composed of 
very dysfunctional people. (GP-9)
… my view is that in the 80s doctors were feeling just as they do now, that many 
of the emotional problems patients come with, they’re relatively poorly equipped 
to deal with and if somebody comes along and says, ‘Here’s a good drug’ and the 
patients like it, then people are tempted to use it because it treats our own pain 
as well as our patients’ pain, ’cos we want to help people and make people feel 
better. So if we give people something and make them feel better, then everybody 
seems to be happier. (GP-5)
Occasionally I’ll prescribe benzodiazepines to drug users you know. I don’t think 
I should be absolutist about it. But I also know that I won’t get any support from 
the drug services if I do that! (GP-20)
Thus, whether GPs adopt a fi rm or liberal prescribing policy, what most 
agree on is that the very need for psychotropic medication for common 
mental health problems cannot be isolated as a clinical need in the skin-
encapsulated patient in the consulting room. Instead, there is recognition 
that life circumstances, past and present, have a pervasive impact on the 
affective and cognitive presentations of distressed patients.
Implications for general practice hereon
Some of the respondents offered a view about the implications of the ben-
zodiazepine problem for future medical practice. One or two (exception-
ally) were not as concerned as their colleagues, because they were tolerant 
of iatrogenic drug dependence; they saw it as part of the territory of medical 
practice in diffi cult circumstances:
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I believe that the controversy has been blown up slightly out of proportion by 
pharmacological and medical purists who for some moral reason disapprove of 
drug dependency. There have been some overdoses – some people have died 
from taking these drugs, but by and large the drugs are harmless. (GP-21)
I think in some ways it has gone too far the other way in that GPs these days can 
be too afraid to use [a benzodiazepine]. I mean if the worst thing you can say 
about these drugs is that they have a potential for dependency, I don’t think that 
is a good enough reason to withdraw. (GP-16)
While these were ‘out-liers’ in the accounts, they may also give some indica-
tion about why appeals to practitioners over the past 20 years to eliminate 
the prolonged use of benzodiazepines have not led to the prescribing habit 
withering away. The fact, noted earlier, that levels of prescribing are a quali-
ty indicator used by English Primary Care Trusts in 2005 suggests that many 
GPs are considered to be still deviating from expectations of best practice. 
They, like their patients, are resistant to change about benzodiazepine use.
Some respondents emphasized that the benzodiazepines were by no means 
unique as a clinical challenge. For example, a number of currently favoured 
drugs were felt to be similarly vulnerable in relation to iatrogenic dependence. 
Codeine-based analgesics, the anti-obesity drugs and Zopiclone (the ‘z’ drugs, 
a newer form of night sedation) were specifi cally noted and a general point 
was made by this respondent: ‘Every drug has that potential. There isn’t a drug 
that hasn’t got potential. Every drug that I use, I always think of the possibility 
of dependency. Sometimes it is a case of which is the worse of two evils’ (GP-
14). This point was reinforced by another respondent with particular reference 
to the SSRIs. These are the newer ‘antidepressant’ drugs, which are used with 
patients who previously would have been given a benzodiazepine or an older 
‘antidepressant’. The latter were effective but toxic. A parallel is evident then 
between these two generations of ‘antidepressants’ and the problems with the 
previous cohort of anxiolytic prescribing. When the new ‘antidepressants’ were 
launched, they were considered to be non-addictive. However, this practitioner 
notes that: ‘The SSRIs are very effective but there is a big problem with 
Seroxat. I have found for two or three years it is very diffi cult to get people 
off – and Prozac to some extent as well’ (GP-12). This point about placing the 
benzodiazepines in the context of other psychotropic drug use leads to the next 
section of the article.
Out with the old and in with the new?
GP authority was undermined by legal and social campaigns of patients and 
pressure groups about the addictive effects of this class of drugs. The ready 
acceptance of blame two decades later by GPs in this study (including even 
younger doctors who could logically distance themselves from past) was 
evident. This is a departure from the victim blaming of patients, when they are 
held responsible for untoward behaviour, though residual aspects of victim 
blaming were evident in the construction of a division between worthy and 
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unworthy patients. However, as we have noted earlier, the classifi cation of 
patients into good and bad marked a departure from previous sociological 
analyses which have emphasized the notion of good or bad patients aligned 
predominantly in relation to access to the sick role being seen as ‘worthy’ or 
‘unworthy’ (Stimson and Webb, 1975; Jeffries, 1979).
One possible professional function of focusing on discredited psycho-
tropic agents is that currently preferred drugs are compared favourably. It 
is commonplace for the current generation of GPs to justify their present 
prescribing norms and use the past inadequacies as a reference point of le-
gitimacy. This pattern or cycle of prescribing legitimacy is not unique to the 
benzodiazepines, as we noted in the fi rst section of this article. For example, 
benzodiazepines compared favourably with the more toxic barbiturates.
More recently, another generation of psychotropic drugs can demonstrate 
the same point. The SSRIs alluded to earlier were hailed as more effective 
and less toxic and dependency forming than the older ‘antidepressants’. 
However, evidence is now coming to light that the drugs are dependency 
forming. They have also been linked to an increased risk of suicidal and 
homicidal action (Healy, 1997).
A second example can be given in relation to ‘anti-psychotic’ medication. 
The older ‘major tranquillizers’ or neuroleptic drugs were superseded by 
the newer ‘atypical anti-psychotics’ during the 1990s. These, more expensive, 
drugs were immediately deemed to be more effective in symptom control 
and were championed for their reduced adverse effects. Moreover, the 
dangers of the older ‘anti-psychotics’, particularly of movement disorders, 
acute dysphoria (dramatic drop in mood) and akathisia (inner restlessness) 
were now acknowledged with concern, whereas previously they had been 
minimized or ignored by clinicians (Brown and Funk, 1986). However, with 
increasing clinical use, problems have come to the fore about the peculiar 
dangers of the ‘atypicals’ (iatrogenic blood disorders and cardio-toxicity).
Comparisons with these other drugs demonstrate that rather than being 
an exception, the benzodiazepines are the rule because psychotropic agents 
are inherently crude or ‘dirty’ drugs (Fisher and Greenberg, 1997). Any 
drug that has a powerful impact on the brain is likely to have extensive 
physiological, experiential and behavioural effects, because they tend to 
have a ‘blunderbuss’ rather than ‘sniper’ impact.
Some of this blunderbuss effect will have adverse consequences for pa-
tients in the form of ‘side-effects’ (a term misleadingly implying a marginal 
or minimal outcome), which may be more dominant in their personal signifi -
cance than any therapeutic benefi t. In the case of psychotropic agents, they 
invariably cause some degree of temporary functional impairment and they 
even may cause permanent structural changes to the major organs of the body 
(Breggin, 1993).
Moreover, all of the classes of psychotropic drug invented and marketed 
since the purported ‘pharmacological revolution’ of the 1950s have tended to 
be portrayed as magic bullets. Terms such as ‘anti-depressant’, ‘anti-anxiety’
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or ‘anti-psychotic’ imply targeted action with a scientifi c rationale, whereas 
most psychotropic agents have been discovered opportunistically, often driv-
en by market forces exploited by the pharmaceutical industry and crudely 
prescribed. It is common for the classes of drugs just cited to be given to pa-
tients with a diagnosis other than that indicated. For example, ‘anti-psychot-
ics’ are given to anxious patients, anxiolytics are used for acute psychotic agi-
tation and ‘anti-depressants’ are given to anxious patients.
According to some commentators (Moncrieff and Crawford, 2001; 
Moncrieff et al., 2005) the psychiatric profession has preferred reifi ed 
descriptions of drug action, such as ‘anti-depressant’ because they justify 
its jurisdiction over mental disorder and legitimize dubious diagnostic 
categories. However, it is less clear, at this stage, whether GPs will follow 
this professional strategy, as they take more and more responsibility for 
mental health problems in the community. The pragmatic need to respond 
to the range of psychosocial features of distress and madness with bio-
medical treatments connects all types of psychotropic drugs. A bio-medical 
response to distress and madness will inevitably and paradoxically be 
both inadequate and yet justifi able within a societal norm of psychosocial 
problems being presented for amelioration or resolution to medical experts. 
In these diffi cult circumstances, prescribers will operate their own version of 
situated rationality. Because of their clinical autonomy, GPs may both share 
and constitute clinical norms on the one hand and differ from one another 
at times on the other (as was evident in the data presented).
Given that all psychotropic agents (prescribed or recreational, legal or 
illicit) expose their recipients to biological, psychological and social risks, 
value judgements are made and applied, by those with the power to do so, 
to divide ‘right’ from ‘wrong’ drugs. An obvious aspect of this is the one 
mentioned earlier about past-prescribed (bad) and present-prescribed 
(good). Another is prescribed (good) and non-prescribed (bad). Another 
is legal (good) and illegal (bad). The social-cognitive reallocation of a 
psychotropic agent from one category to another disrupts existing norms and 
so creates a risk to norm maintenance. Examples here are the controversies 
about the medicinal use of cannabis and the sale of prescribed drugs (like 
methadone and the benzodiazepines) on the streets.
Thus the end of this article brings us up against a wider sociological 
consideration, which is beyond its scope to explore fully – the role of GPs 
as risk managers on behalf of a moral order, which is now a ‘risk society’ 
(Beck, 1992) and preoccupied by the ‘politics of anxiety’ (Turner, 1991). The 
arena of contention about drug use and the semantics it contains reveals 
a good/bad dichotomy refl ecting this context of risk management (Swartz 
et al., 1998). For example, do people ‘use’, ‘abuse’ or ‘misuse’ ‘substances’? 
At what point is alcohol a ‘bad’ rather than a ‘good’ habit? Why is the use 
of methadone by opiate addicts good but the use of heroin bad? These 
questions suggest that the moral, logical or empirical isolation of particular 
drugs (like benzodiazepines) is not warranted. Moreover, attempts at such 
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isolation may obscure our understanding of the precarious state of norm 
maintenance around the human intake of substances, past or present, 
prescribed or not, legal or illegal, that affect thoughts, feelings and actions.
Conclusion
This article started by exploring what appeared to be a straightforward 
assumption – that one group of psychotropic drugs, the benzodiazepines, 
requires special considerations about clinical risk management in primary 
care, because they are an unusual example of an iatrogenic legacy from 
primary care colleagues. The study of GP views began to problematize this 
assumption in a number of ways. This was a qualitative study intended to 
illuminate ways of thinking in a particular group of GPs – as it turned out a 
self-selected group who were not always directly responsible for prescribing 
benzodiazepines in the 1980s. However, within this context, most seemed to 
take the clinical risks seriously and own the responsibility for current good 
practice, as well as for the rectifi cation of inherited clinical iatrogenesis.
In this respect, there appears to have been a cultural shift in the way 
in which GPs have viewed the risks associated with benzodiazepine use. 
Giddens (1991) and Beck (1992) have both asserted that our recent ‘risk 
society’ is associated with a greater consciousness of risk than in the past. 
Although since the 1990s GPs have acknowledged the problem of over-
prescribing as a multifactorial one with complex and psychological roots 
(Hamilton et al., 1990), GP narratives from this study problematized their 
professional role and risks of a technological problem more than their pre-
decessors. Based on past behaviour the latter were (until the crisis over 
prescribing was brought to a head) more inclined to dismiss or underrate 
the risk that arose from what was seen as an innovative and welcome 
development in science and technology.
Notwithstanding this shift in perspective about the risks of benzodi-
azepines, their prescription has not become a total taboo in primary care. In 
common with the fi ndings of the study by Parr et al. (2006) undertaken in an 
Australian context, British GPs were knowledgeable and skilled in describ-
ing steps required for a successful cessation of benzodiazepine use. None the 
less, not only did the majority of the respondents plead for the ‘deserving’ 
patient, a few even minimized the problem of iatrogenic addiction, feeling 
that ‘medical purists’ had overdrawn the clinical and social problems associ-
ated with the drugs. This tolerance of addiction in turn raises some broader 
questions about whether benzodiazepines are that unusual. It may also ac-
count for why health service managers still struggle to bring the problem of 
benzodiazepine use under acceptable local political control.
Comparisons with other drugs (prescribed or self-administered) suggest 
that the benzodiazepines are not the exception but the rule in a number of 
ways. They, like other psychotropic drugs, are rather crude and dependency 
forming and are compared unfavourably with past alternatives, which are 
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now discredited. Benzodiazepines, like other drugs, are part of a set of 
impermanent dichotomizations. Forty-fi ve years ago benzodiazepines were 
generally ‘good’ but now they are generally ‘bad’ (with some exceptions 
pointed up earlier). Such divisions could be pointed up about all of the 
other classes of prescribed psychotropic agents.
Moreover, the scandal surrounding the benzodiazepines and highlighted 
by the mid-1980s in the UK was much delayed, when the evidence about 
them is viewed with hindsight. Given that the fi rst lawsuit about them 
appeared in 1967, it could be argued that undergraduate and postgraduate 
medical education was in a position to alter radically the trajectory of 
prescription levels, as early as 1970. But this did not occur.
Again the benzodiazepines are not unique in this regard. The same 
point about over-use and under-criticism can be found in the cases of 
‘anti-depressants’ and ‘anti-psychotics’. In their prescribed form, they are 
all utilized in a bio-medical arena in which the individual manifestations 
of the psychosocial causes and consequences of distress and madness are 
risk-managed. The enormity and sometimes futility of this task ensure 
that inadequate and imperfect medical measures are used in response 
to mental health problems. They also ensure that corrective criticism of 
such inadequacies and imperfections is slow to develop and diffi cult to 
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